Probiotics, Prebiotics & Synbiotics
What works, what doesn't, and why strain matters more than species.
What's covered
- 01Definitions: probiotic, prebiotic, synbiotic, postbiotic
- 02Strain specificity: L. rhamnosus GG ≠ L. rhamnosus LR04
- 03Antibiotic-associated diarrhea: S. boulardii, L. rhamnosus GG
- 04IBS: Bifidobacterium infantis 35624, VSL#3/De Simone Formulation
- 05Necrotizing enterocolitis prevention in premature infants
- 06Prebiotics: FOS, GOS, inulin — feeding the residents
- 07Consumer market vs clinical evidence disconnect
By the end of this module you will be able to
- L01Define probiotics, prebiotics, synbiotics, and postbiotics with correct terminology.
- L02Explain why probiotic effects are strain-specific and not generalizable across species.
- L03Identify conditions with high-quality RCT evidence for specific probiotic strains.
- L04Critically evaluate consumer probiotic marketing claims.
What you should walk away believing
- →Strain matters — not all Lactobacillus are the same. Clinical evidence is for specific strains, not genera.
- →Strong evidence exists for AAD prevention, NEC prevention in preemies, and specific IBS symptoms.
- →Most consumer probiotics have no strain-specific clinical evidence for the conditions they imply treating.
- →Prebiotics (fiber, FOS, GOS) may be more reliably beneficial than probiotics for most people.
What this means for you
Probiotics are live bacteria taken as supplements or found in fermented foods. The most important thing to know: not all probiotics are the same. The specific strain matters enormously. Some strains have good evidence for preventing antibiotic-related diarrhea, while others have been studied and found to do nothing. Most grocery-store probiotics have never been tested for the health claims on their labels.
Evidence-based prescribing requires strain-level specificity. Grade A/B evidence: S. boulardii CNCM I-745 for C. diff-associated and AAD prevention; L. rhamnosus GG for pediatric AAD; B. infantis 35624 for IBS global symptoms. For NEC prevention in VLBW infants, multi-strain preparations reduce incidence (NNT ~33). Most consumer products lack strain identification, adequate CFU, or relevant clinical trials. AGA guidelines recommend probiotics only for specific clinical contexts.
The probiotic colonization question is partially answered by Zmora et al. (2018): orally administered probiotics show person-specific mucosal colonization — some hosts resist, others permit. Resistance is associated with higher baseline diversity. This explains inter-individual variability in probiotic trial outcomes and argues for personalized approaches. Next-gen probiotics (Akkermansia, F. prausnitzii, engineered strains) are entering clinical development.
The probiotic-for-everything patient
A 50-year-old with well-controlled T2DM takes 4 different probiotic supplements daily (total cost ~$180/month), each marketed for different benefits: 'gut health,' 'immune support,' 'mood,' and 'metabolism.' None list specific strain designations. He asks if he should add a fifth for 'brain health.'
How would you evaluate his current regimen, explain strain specificity vs generic labeling, and make evidence-based recommendations?
What the data says
Test yourself
Spaced review
Key terms & abbreviations
- Probiotic
- Live microorganisms that, when administered in adequate amounts, confer a health benefit on the host (WHO/FAO definition).
- Prebiotic
- A substrate that is selectively utilized by host microorganisms conferring a health benefit (ISAPP definition).
- Synbiotic
- A mixture comprising live microorganisms and substrate(s) selectively utilized by host microorganisms.
- Postbiotic
- A preparation of inanimate microorganisms and/or their components that confers a health benefit.
Optional deeper dive
- Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features — Zmora N et al., Cell 2018↗
- AGA Clinical Practice Guidelines on the Role of Probiotics in GI Disorders — Su GL et al., Gastroenterology 2020↗